Search Within

Isabelle C Riviere

  1. "Jae Park"
  2. "American Society of Hematology"
  3. "Center for Hematologic Malignancies"
  4. "Kevin Curran"
Formats
  1. Meeting Abstract (9)
  2. Journal Article (3)
Groups
  1. Adult Leukemia (12)
  2. Center for Hematologic Malignancies (12)
  3. Department of Medicine (12)
  4. GSK Faculty (12)
  5. Hematologic Malignancies Research (12)
  6. Hematologic Malignancies, Division of (12)

More Groups

People
  1. Jae Park (12)
  2. Kevin Curran (12)
  3. Renier Brentjens (12)
  4. Craig Sauter (10)
  5. Michel Sadelain (10)
  6. Xiuyan Wang (10)

More People

Years
  1. 2021 (1)
  2. 2019 (2)
  3. 2018 (1)
  4. 2017 (2)
  5. 2015 (2)
  6. 2014 (3)

More Years

Publications
  1. Blood (12)
Publishers
  1. American Society of Hematology (12)

Results (12)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy
    Journal Article

    Wudhikarn, K.; Flynn, J. R.; Rivière, I.; Gönen, M.; Wang, X.; Senechal, B.; Curran, K. J.; Roshal, M.; Maslak, P. G.; Geyer, M. B.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
    Journal Article

    Curran, K. J.; Margossian, S. P.; Kernan, N. A.; Silverman, L. B.; Williams, D. A.; Shukla, N.; Kobos, R.; Forlenza, C. J.; Steinherz, P.; Prockop, S.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma
    Journal Article

    Sauter, C. S.; Senechal, B.; Rivière, I.; Ni, A.; Bernal, Y.; Wang, X.; Purdon, T.; Hall, M.; Singh, A. N.; Szenes, V. Z.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Clinical responses and pharmacokinetics of MCARH171, a human-derived BCMA targeted CAR T cell therapy in relapsed/refractory multiple myeloma: Final results of a phase I clinical trial
    Meeting Abstract

    Mailankody, S.; Ghosh, A.; Staehr, M.; Purdon, T. J.; Roshal, M.; Halton, E.; Diamonte, C.; Pineda, J.; Anant, P.; Bernal, Y.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Development and evaluation of a human single chain variable fragment (scFv) derived BCMA targeted CAR T Cell vector leads to a high objective response rate in patients with advanced MM
    Meeting Abstract

    Smith, E. L.; Mailankody, S.; Ghosh, A.; Masakayan, R.; Staehr, M.; Purdon, T. J.; Halton, E.; Diamonte, C.; Anant, P.; Bernal, Y.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • High dose cyclophosphamide and pre-treatment disease burden dictate response and survival in a multicenter clinical trial using CD19-specific CAR T cells for relapsed/refractory B-ALL
    Meeting Abstract

    Curran, K. J.; Margossian, S. P.; Kernan, N. A.; Silverman, L. B.; Park, J. H.; Sauter, C. S.; Smith, E. L.; Boulad, F.; Cancio, M. I.; Forlenza, C.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Multi-center clinical trial of CAR T cells in pediatric/young adult patients with relapsed B-cell ALL
    Meeting Abstract

    Curran, K. J.; Riviere, I.; Silverman, L. B.; Kobos, R.; Shukla, N.; Steinherz, P. G.; Boulad, F.; Prockop, S.; Scaradavou, A.; Margossian, S. P.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Implications of minimal residual disease negative complete remission (MRD-CR) and allogeneic stem cell transplant on safety and clinical outcome of CD19 targeted 19-28z CAR modified T cells in adult patients with relapsed, refractory B-cell ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y.; Purdon, T.; Halton, E.; Wang, Y.; Curran, K. J.; Sauter, C. S.; Sadelain, M.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Interim safety analysis: A phase I trial of high dose therapy and autologous stem cell transplantation followed by infusion of chimeric antigen receptor modified T-cells (19-28z CAR-T) directed against CD19+B-cells for relapsed and refractory aggressive B cell non-Hodgkin lymphoma (B-NHL)
    Meeting Abstract

    Sauter, C. S.; Riviere, I.; Bernal, Y. J.; Wang, X. Y.; Purdon, T. J.; Yoo, S.; Moskowitz, C. H.; Giralt, S.; Matasar, M. J.; Curran, K. J.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • CD19-targeted 19-28z CAR modified autologous T cells induce high rates of complete remission and durable responses in adult patients with relapsed, refractory B-cell ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y. J.; Yoo, S.; Purdon, T.; Halton, E.; Quintanilla, H.; Curran, K. J.; Sauter, C. S.; more...
    Blood (2014)

    Fulltext@MSK | Save